Hilgendorf, Inken and Wolff, Daniel (2013) Treatment options for graft-versus-host disease. EXPERT OPINION ON ORPHAN DRUGS, 1 (9). pp. 731-743. ISSN 2167-8707
Full text not available from this repository. (Request a copy)Abstract
Introduction: Graft-versus-host disease (GVHD) is the leading cause formortality and morbidity after allogeneic hematopoietic stem cell transplantation (alloHSCT). Here, we discuss different options for systemic treatment of acute and chronic GVHD. Areas covered: The literature search was performed using the Pubmed database. Only English literature was considered with the main focus on reported clinical trials and retrospective analysis. Expert opinion: Steroids remains the backbone in first-line treatment of GVHD. Second-line treatment of acute or chronic GVHD is less well defined, due to the lack of evidence from randomized trials. Since the prognosis of steroid-refractory GVHD is often poor, new strategies to prevent and treat GVHD and to evaluate response to treatment are clearly needed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; REGULATORY T-CELLS; BONE-MARROW-TRANSPLANTATION; ANTI-THYMOCYTE GLOBULIN; REFRACTORY ACUTE GVHD; LOW-DOSE METHOTREXATE; SCLERODERMATOUS CHRONIC GVHD; TOTAL-LYMPHOID IRRADIATION; CLINICAL-TRIALS NETWORK; RECEPTOR FUSION PROTEIN; allogeneic hematopoietic stem cell transplantation; bone marrow transplantation; GVHD; immunosuppressive therapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Petra Gürster |
| Date Deposited: | 18 Jun 2020 10:36 |
| Last Modified: | 18 Jun 2020 10:36 |
| URI: | https://pred.uni-regensburg.de/id/eprint/16056 |
Actions (login required)
 |
View Item |
